A minimalist approach to transcatheter aortic valve implantation (TAVI), without sedation, was noninferior to the standard ...

The ESC now recommends TAVR be considered, even for asymptomatic patients, reflecting a step-change from the longstanding ...

Over the past several days, the leaders in cardiology convened in Madrid for the European Society of Cardiology (ESC) ...

Abbott wins CE Mark in Europe for expanded Navitor use, boosting its Structural Heart business and lifting ABT stock.

Background Previous research on congenital aortic stenosis (AS) mainly focused on children, while data on long-term outcomes ...

Apollo Hospitals, Chennai performs first implantation of Edwards SAPIEN 3 Ultra RESILIA valve, offering safer outcomes for ...

The global market for transcatheter aortic valve replacement (TAVR) is seeing exponential growth in both developed and ...

Edwards Lifesciences has launched a next-generation transcatheter heart valve platform in India, providing a durable and ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic stenosis (AS), a valvular heart condition that can be ...

Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing ...

The patient with severe aortic stenosis is relatively "afterload fixed and preload dependent" -- meaning cardiac output does not increase with after-load reduction.

The use of transcatheter aortic valve implantation (TAVI) to treat aortic stenosis has rapidly evolved and TAVI procedures now outnumber surgical replacement in Europe.   Minimalist treatment ...